ClinicalTrials.gg

Program

Itraconazole

Also written as “itraconazole”, “Itraconazole (200 mg)” and “Itraconazole Powder”.

Its studies are mostly in HIV Infections · Hematologic Neoplasms · Asthma · Neutropenia · Onychomycosis, led by 9 companies.

Furthest: phase 4, since Feb 13, 200932 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson100 open or runningphase 4since Feb 13, 2009Nov 2, 1999none ahead
AstraZeneca60 open or runningphase 1since Jul 12, 2013Jul 12, 2013none ahead
GlaxoSmithKline30 open or runningphase 3since Jul 25, 2006Jul 25, 2006none ahead
Pfizer30 open or runningphase 1since Mar 27, 2014Mar 27, 2014none ahead
Pulmatrix30 open or runningphase 2since May 14, 2019Feb 5, 2018none ahead
GRIN Therapeutics21 open or runningphase 1since Apr 11, 2025Apr 11, 2025none ahead
Lomond Therapeutics20 open or runningphase 1since May 1, 2024May 1, 2024none ahead
mayne-pharma-international-pty-ltd20 open or runningphase 4since Dec 2, 2015Dec 2, 2015none ahead
Boryung Pharmaceutical10 open or runningphase 1since Jul 7, 2015Jul 7, 2015none ahead

Also a collaborator on its studies: parexel, avance-clinical-pty-ltd, arvinas-estrogen-receptor-inc, cambridge-cognition-ltd and covance.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Nov 2, 1999.

  1. Sep 6, 2016Phase 4 study in Hematologic NeoplasmsJohnson & Johnson · NCT02895529 · 61 enrolled · China
  2. Feb 5, 2018Pulmatrix's first study: phase 1 study in AsthmaNew to PulmatrixPulmatrix · NCT03479411 · 58 enrolled · United Kingdom
  3. Feb 14, 2019Phase 1 study in Heart FailureAstraZeneca · NCT03843060 · 14 enrolled · United States
  4. Apr 18, 2019Phase 4 study in MycosesJohnson & Johnson · NCT03923010 · 40 enrolled · India
  5. May 14, 2019Phase 2 study in Aspergillosis, Allergic BronchopulmonaryPulmatrix · NCT03960606 · 7 enrolled · United States, Australia, India and more
  6. Dec 15, 2020Phase 1 study in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)AstraZeneca · NCT04712396 · 11 enrolled · Germany
  7. Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
  8. Sep 8, 2022Phase 1 study in HealthyPfizer · NCT05538312 · 12 enrolled · Belgium
  9. Dec 1, 2022Phase 2 study in AsthmaPulmatrix · NCT05667662 · 8 enrolled · United States, Australia, France and more
  10. Apr 5, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06357520 · 14 enrolled · United States
  11. May 1, 2024Lomond Therapeutics's first study: phase 1 study in AMLNew to Lomond TherapeuticsLomond Therapeutics · NCT06399315 · 112 enrolled · Australia
  12. Jan 16, 2025Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellLomond Therapeutics · NCT06787131 · 104 enrolled · Australia
  13. Apr 11, 2025GRIN Therapeutics's first study: phase 1 study in Tuberous SclerosisNew to GRIN TherapeuticsGRIN Therapeutics · NCT06965881 · 30 enrolled · Australia
  14. Oct 8, 2026Phase 1 study in Healthy Adult ParticipantsGRIN Therapeutics · NCT07884734 · 36 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07884734Healthy Adult Participants · United States1Active, not recruitingGRIN TherapeuticsOct 31, 202636
NCT06965881Tuberous Sclerosis · Australia1TerminatedGRIN TherapeuticsJul 8, 202530
NCT06787131Leukemia, Lymphocytic, Chronic, B-Cell · Australia1CompletedLomond TherapeuticsJul 4, 2025104
NCT06399315AML · Australia1CompletedLomond TherapeuticsJun 30, 2025112
NCT06357520Healthy Participants · United States1CompletedAstraZenecaJun 17, 202414
NCT05667662Asthma · United States, Australia, France and more2TerminatedPulmatrixFeb 27, 20248
NCT05538312Healthy · Belgium1CompletedPfizerApr 24, 202312
NCT04959266Advanced Solid Tumours · United States, Spain1TerminatedAstraZenecaJun 1, 20225
NCT04712396Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) · Germany1CompletedAstraZenecaMar 25, 202111
NCT03960606Aspergillosis, Allergic Bronchopulmonary · United States, Australia, India and more2TerminatedPulmatrixJul 14, 20207
NCT03923010Mycoses · India4TerminatedJohnson & JohnsonMar 25, 202040
NCT03843060Heart Failure · United States1CompletedAstraZenecaApr 1, 201914
NCT03479411Asthma · United Kingdom1CompletedPulmatrixJun 28, 201858
NCT02895529Hematologic Neoplasms · China4TerminatedJohnson & JohnsonMay 2, 201861
NCT02755857Neutropenia · Australia2Completedmayne-pharma-international-pty-ltdDec 201620
NCT02621905Neutropenia · Australia4Completedmayne-pharma-international-pty-ltdNov 201640
NCT02493738Dermatomycoses · Korea, Republic of1CompletedBoryung PharmaceuticalOct 201524
NCT02131298Healthy · United States1CompletedPfizerJun 201412
NCT02130661Alzheimer Disease1WithdrawnGlaxoSmithKlineJan 20180
NCT02100553Obesity · United States1CompletedPfizerJun 201424
NCT02093728Solid Tumours · United States1CompletedAstraZenecaJun 201426
NCT01900028Neoplasms · Belgium, Denmark, Netherlands and more1CompletedAstraZenecaApr 201485
NCT01823289Lung Diseases, Fungal4CompletedJohnson & JohnsonDec 200871
NCT00871728Onychomycosis4CompletedJohnson & JohnsonMay 2009132
NCT00695071Healthy · United States1CompletedGlaxoSmithKlineJul 200816
NCT00356915Onychomycosis · United States, Canada, Dominican Republic and more3CompletedGlaxoSmithKlineOct 20081,381
NCT00002438HIV Infections · United States–CompletedJohnson & Johnson
NCT00002370HIV Infections · United States–CompletedJohnson & Johnson36
NCT00002341Candidiasis, Oral · United States–CompletedJohnson & Johnson
NCT00002159HIV Infections · United States3CompletedJohnson & Johnson60
NCT00002133Candidiasis, Oral · United States–CompletedJohnson & Johnson
NCT00002132Candidiasis · United States–CompletedJohnson & Johnson

How it is read

Names in the registry

  • “Itraconazole”, 40 entries
  • “itraconazole”, 5 entries
  • “Itraconazole (200 mg)”, 4 entries
  • “Itraconazole Powder”, 2 entries
  • “Lozanoc”, 2 entries

Codes read as this program: PUR1900.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
Itraconazole (Johnson & Johnson): development program | ClinicalTrials.gg